Social Determinants of Health in Metabolic Dysfunction‐Associated Steatotic Liver Disease and All‐Cause/Cause‐Specific Mortality

Alimentary Pharmacology & Therapeutics · 2025-10-15 · 6 citations

BACKGROUND: Social determinants of health (SDoH) are the preventable health inequities, and the associations between SDoH and health outcomes among individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) remain unclear. AIMS: We investigated the relationship between SDoH and mortality in individuals with MASLD in the US. METHODS: We conducted a retrospective analysis using data from the 2007-2016 National Health and Nutrition Examination Survey, with follow-up mortality data assessed through 2019. SDoH score was derived from questionnaires, and MASLD was defined using non-invasive panels and cardiometabolic criteria. Cox regression models were used to evaluate the association between SDoH and all-cause/cause-specific mortality among individuals with MASLD. RESULTS: We analysed 12,321 individuals with MASLD (mean age: 47.0 years; 48.4% males). Over a median follow-up period of 7.6 years, higher SDoH scores were associated with progressively increased hazards of all-cause mortality. The results remained consistent in a multivariable model. Additionally, higher unfavourable SDoH scores were associated with increased cardiovascular and cancer-related mortality. Specifically, there was a 32% increase in hazards for all-cause mortality (hazard ratio [HR]: 1.32, 95% confidence interval [CI]: 1.25-1.38) and increases of 29% and 21% for cardiovascular (HR: 1.29, 95% CI: 1.19-1.40) and cancer-related mortality (HR: 1.21, 95% CI: 1.07-1.36), respectively, for each one-point increase in SDoH score. Employment status, food insecurity, family income, private insurance coverage, and marital status were independently associated with all-cause mortality in individuals with MASLD. CONCLUSIONS: This US population-based study demonstrates that SDoH scores are dose-dependently associated with increased all-cause/cause-specific mortality among individuals with MASLD.

Contemporary trends in extrahepatic mortality of chronic liver disease in the United States from 2014 to 2023

Clinical and Molecular Hepatology · 2025-07-28 · 1 citations

Dietary vitamin E intake in metabolic dysfunction–associated steatotic liver disease and all-cause/cause-specific mortality

European Journal of Gastroenterology & Hepatology · 2025-08-20

AIMS: We investigated the independent association between dietary vitamin E intake among individuals with metabolic dysfunction-associated steatotic liver disease (MASLD) and all-cause and cause-specific mortality in a representative sample of the USA. METHODS: We used the 2007-2014 US National Health and Nutrition Examination Survey with mortality follow-up through 2019 (median: 8.6 years). Cox regression models were used to assess the association between dietary vitamin E intake in MASLD and all-cause and cause-specific mortality. RESULTS: Among the 10 193 individuals with MASLD (mean age: 46.8 years and male: 48.0%), greater dietary vitamin E intake was correlated with a gradual reduction in the risk of all-cause mortality, which remained significant after adjustment for clinical and metabolic risk factors (hazard ratio: 0.68, 95% confidence interval: 0.50-0.94 for the fourth quartile compared with the first quartile; P for trend = 0.018). This association remained more pronounced in older populations, males, and non-Hispanic Whites than in their counterparts. Increased dietary vitamin E intake demonstrated trends associated with reduced cancer-related mortality. CONCLUSION: Higher dietary vitamin E intake in MASLD was associated with a lower risk of all-cause mortality.

890: SGLT-2 INHIBITOR THERAPY IN LIVER TRANSPLANT RECIPIENTS MAY REDUCE THE RISK OF DEVELOPING NEW HEPATOCELLULAR CARCINOMA

Gastroenterology · 2025-05-01

Current Burden of Lean Metabolic Dysfunction‐Associated Steatotic Liver Disease Among <scp>US</scp> Adults, 2017–2023

Alimentary Pharmacology & Therapeutics · 2025-01-11 · 7 citations

Our study investigated the prevalence of lean steatotic liver disease (SLD) and its subcategories, including metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction-related and alcohol-related SLD (MetALD), and alcohol-related liver disease (ALD) among lean adults in the US. Analysing data from 2965 lean adults (≥ 18 years) from the National Health and Nutrition Examination Survey (2017-2023), we found the age-adjusted prevalence of lean SLD to be 12.8%. Specifically, the prevalence was 9.3% for lean MASLD, 1.3% for MetALD and 1.0% for ALD. Notably, within the MASLD group, significant fibrosis, advanced fibrosis, and cirrhosis were observed in 5.6%, 2.4% and 2.0%, respectively.

Addressing the burden of steatotic liver disease: The role of transient elastography: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”

Clinical and Molecular Hepatology · 2025-02-13

Addressing the Burden of Steatotic Liver Disease: The Role of Transient Elastography: Correspondence to editorial on “Vibration-controlled transient elastography in shaping the epidemiology and management of steatotic liver disease”

The burden of steatotic liver disease before and during the COVID-19 pandemic: Correspondence to editorial on “Current burden of steatotic liver disease and fibrosis among adults in the United States, 2017-2023”

Clinical and Molecular Hepatology · 2025-02-17 · 4 citations

The Burden of Steatotic Liver Disease before and during the COVID Pandemic Correspondence to editorial on “Revealing the importance of a multidisciplinary approach to reducing the global burden of SLD in the COVID-19 pandemic (CMH-2025-0019)”

Cost-effectiveness analysis of a new paradigm to simplify testing, monitoring and treatment of hepatitis C virus in the United States

Cost Effectiveness and Resource Allocation · 2025-06-04

The hepatitis C virus (HCV) testing and treatment pathway in the United States (US) includes a range of tests and appointments causing delays and loss to follow-up. We assessed the cost-effectiveness of simplifying the pathway using an economic model to estimate health outcomes, cost differences and incremental cost per quality-adjusted life year (QALY) and life year (LY) of the new paradigm compared to the other scenarios. The analysis compared three scenarios, one based on treatment guidelines, one based on real-world practice and a hypothetical scenario with a simplified pathway ("new paradigm"); these differed in testing and treatment process steps and times. The new paradigm resulted in cost reductions between $19,751 and $16,448, and excess QALYs between 0.42 and 0.70, suggesting that simplifying the US HCV patient pathway may be cost-effective and allows a quicker path to successful treatment and reduce the number of patients lost to follow-up.

Health Service Utilization, Substance Use Treatment and Death in Patients With Opioid Use Disorder and Hepatitis C: A Prospective Cohort Study With Administrative Database Linkage

Drug and Alcohol Dependence · 2025-02-01 · 1 citations

Impact of Hcv Status on Healthcare Utilization for Opioid Related Harms Among Patients Receiving Opioid Agonist Therapy

Drug and Alcohol Dependence · 2025-02-01 · 1 citations